Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy

Current HIV Research

Volumn 10, Issue 6, 2012, Pages 532-538

  Sinha, S ^a   Shekhar, R C ^a   Ahmad, H ^a   Kumar, N ^a   Samantaray, J C ^a   Sreenivas, V ^a   Khan, N H ^a   Mitsuyasu, R T ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ARV; DRMS; HIV 1; Protease; Resistance; Reverse transcriptase

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE PLUS LAMIVUDINE EFAVIRENZ; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; DRUG RESISTANCE MUTATION; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREVALENCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV-1; HUMANS; INDIA; MALE; PHYLOGENY; PREVALENCE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 84866317090     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212802429785     Document Type: Article

References (34)

1. The United Nations Joint Programme on HIV/AIDS (UNAIDS). 2010 report on the global HIV/AIDS epidemic. Geneva: UNAIDS. Technical Report number: UNAIDS/10.11E; 2010.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998; 338: 853-860.
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-1730.
4. Kumarasamy N, Solomon S, Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005; 41: 1525-1528.
5. National AIDS Control Organization (NACO). 2009-2010: Annual Status report. New Delhi: Department of AIDS Control, Ministry of Health and Family Welfare, Govt. of India; 2010.
6. Kumar S. India's treatment programme for AIDS is premature. Br Med J 2004; 328: 70.
7. Clavel F, Hance AJ. HIV drug resistance. N Eng J Med 2004; 350: 1023-1035.
8. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systemic review of clinical trials. Clin Infect Dis 2008; 47: 712-722.
9. Deshpande A, Recordon-Pinson P, Deshmukh R, et al. Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India and detection of rare resistance mutations. AIDS Res Hum Retroviruses 2004; 20: 1032-1035.
10. Hira SK, Panchal K, Parmar PA, Bhatia VP. High resistance to antiretroviral drugs: the Indian experience. Int J STD AIDS 2004; 15: 173-177.
11. Lakshmi R, Ramesh K, Narayanan PR, Swaminathan S. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients. AIDS Res Hum Retroviruses 2009; 25: 1179-1185.
12. Lakshmi R, Ramesh K, Hanna LE, Narayanan PR, Swaminathan S. Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India. IndianJ Med Res 2010; 132: 509-512.
13. National AIDS Control Organization (NACO). HIV Testing policy and functioning of VCTC. New Delhi: Department of AIDS Control, Ministry of Health and Family Welfare, Govt. of India; 2001.
14. National AIDS Control Organization (NACO). National AIDS Prevention and Control Policy. New Delhi: Department of AIDS Control, Ministry of Health and Family Welfare, Govt. of India; 2002.
15. National AIDS Control Organization (NACO). Antiretroviral Therapy guidelines for HIV infected adults and adolescents including post exposure prophylaxis. New Delhi: Department of AIDS Control, Ministry of Health and Family Welfare, Govt. of India; 2007.
16. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organisation/ HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 2008; 13 Suppl 2: 49-57.
17. Eshleman SH, Hackett J Jr, Swanson P, et al. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol 2004; 42: 2711-2717.
18. Stanford HIV Drug Resistance Database [Internet]. Available from: http://hivdb.stanford.edu//index.html (accessed August 2, 2011).
19. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: Improving the sensitivity of progressive multiple sequence weighting, position specific alignment through sequence weight matrix choice. Nucleic Acids Res 1994; 22: 4673-4680.
20. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for molecular evolutionary genetic analysis and sequence alignment. Brief Bioinform 2004; 5: 150-163.
21. Sen S, Tripathy S P, Patil A A, et al. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007; 23: 1303-1308.
22. Deshpande A, Jauvin V, Magnin N, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses 2007; 23: 335-340.
23. Madhavan V, Shanmugam S, Shanmugasundararam U, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther 2009; 14: 1005-1009.
24. Kumarasamy N, Madhavan V, Venkatesh K K, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: Implications for secondline options in resource-limited settings. Clin Infect Dis 2009; 49:306-309.
25. Gupta A, Saple D G, Nadkarni G, et al. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India. AIDS Res Hum Retroviruses 2010; 26: 25-31.
26. Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol 2004; 29: 152-159.
27. Lole KS, Bollinger RC, Paranjape RS, et al. Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype CInfected Seroconverters in India, with Evidence of Intersubtype Recombination. J Virol 1999; 73: 152-160.
28. Khan IF, Vajpayee M, Prasad VSP, Seth P. Genetic diversity of HIV type 1 subtype C env gene from India. AIDS Res Hum Retroviruses 2007; 23: 934-940.
29. Gadkari DA, Moore D, Sheppard HW, Kulkarni SS. Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J Med Res 1998; 107: 1-9.
30. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2: e112.
31. Brenner B TD, Oliveira M, Moisi D, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers crossresistance to non nucleoside reverse transcriptase inhibitors. AIDS 2003; 17: F1-F5.
32. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50: 4182-4185.
33. Marconi V C, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in Kwa Zulu Natal, South Africa. Clin Infect Dis, 2008; 46: 1589-1597.
34. World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach- 2006 revision. WHO; 2006. Available from: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. (accessed April 13, 2011).